Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs)), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Others), By Sample (Tissue, Blood, Saliva and Buccal Swab, Others), By Method (DNA, RNA, Proteins), By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, Other Cancer Types), By Application (Clinical, Research), By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Multicancer Screening Market was valued at USD 1.41 Billion in 2024 and is expected to reach USD 3.29 Billion by 2030 with a CAGR of 15.12%. The Global Multicancer Screening Market is experiencing significant growth driven by rising awareness of early cancer detection, advancements in genomic technologies, and an increasing prevalence of various cancer types worldwide. With cancer continuing to be a leading cause of mortality, the emphasis on early and accurate diagnosis has become more pronounced. Healthcare systems are increasingly prioritizing preventive care, encouraging investment in liquid biopsy techniques, next-generation sequencing (NGS), and bioinformatics tools to detect multiple cancers at earlier stages through non-invasive methods. Supportive government initiatives, such as the Cancer Moonshot program and international funding for early detection trials, are bolstering innovation and commercial deployment of multicancer early detection (MCED) tests. Strategic collaborations between diagnostic companies and academic institutions are also accelerating clinical validation and deployment of such tests.

The market is witnessing a strong trend toward the integration of AI and machine learning in MCED platforms to improve detection accuracy and reduce false positives. AI-powered algorithms help analyze complex genomic data and identify cancer signals from circulating tumor DNA (ctDNA) and other biomarkers. Another notable trend is the shift from organ-specific diagnostics to comprehensive, multi-cancer panels that screen for numerous cancers in a single test, reducing the need for multiple procedures. Key industry players are increasingly focusing on longitudinal real-world evidence studies to evaluate the long-term impact of MCED tests on clinical outcomes and healthcare costs. Liquid biopsy-based screening is gaining momentum due to its convenience and lower invasiveness compared to traditional biopsy methods, making it suitable for population-wide screening strategies. This technological evolution is transforming how clinicians approach cancer diagnosis and is reshaping the preventive healthcare landscape.

Despite strong growth prospects, the market faces challenges related to regulatory approvals, clinical utility validation, and high costs of implementation. Many emerging MCED technologies require extensive clinical trials and long-term data to gain acceptance from regulatory bodies and payers. The complexity of interpreting multi-cancer signals with specificity and sensitivity poses a technical barrier, especially for cancers with low biomarker prevalence. Limited awareness among clinicians and patients regarding the availability and reliability of such tests further constrains widespread adoption. High testing costs and a lack of reimbursement frameworks in some regions add financial strain, particularly in resource-limited healthcare systems. Addressing these challenges will require collaborative efforts from policymakers, industry stakeholders, and medical communities to ensure that MCED becomes an integral part of cancer prevention and public health strategies.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

Cancer is one of the leading causes of death worldwide, and the incidence of cancer is expected to continue to rise in the coming years due to various factors such as aging populations, changes in lifestyle, and environmental factors. The most common type of cancer prevailing in the regions of developing countries is breast cancer. For instance, in the United States of America, around 3,00,590 new cases of breast cancer were diagnosed of breast cancer in 2023. Another type of cancer, which is emerging in the world followed by breast cancer comprises of lung cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, and cervical cancer. According to the report published by the World Health Organization (WHO) in 2022, around 2.26 million cases of breast cancer were worldwide in 2020, followed by 2.21 million cases of lung cancer, 1.93 million cases of colon and rectum cancer, 1.41 million cases of prostate cancer, 1.20 million cases of skin cancer (non-melanoma) and 1.09 million cases of stomach cancer. 

The growing prevalence of cancer in the world is resulting in a noticeable rise in the mortality rate of each country with every passing year. As per the report published by World Cancer Research Fund on global cancer rates, it has been concluded that Denmark has recorded the highest cancer rate of 326.1 cases per 1,00,000 population, followed by Ireland with 317 cases, Australia with 314.1 cases, New Zealand with 309.2 cases and Belgium with 306.8 per 1,00,000 population and so on. The growing prevalence of several kinds of cancers is increasing the demand for multicancer screening devices in the world which can detect symptoms of multiple cancer beforehand and can thereby decrease the mortality rate of the world, which is further expected to propel the global multicancer screening market during the forecast period.

Growth in Government Support

The Multicancer screening market refers to the development and sale of tests and services that can detect various types of cancers in individuals. Government support can play a significant role in driving growth in this market. Many governments are investing in research and development of cancer screening tests and technologies. For instance, the National Cancer Institute in the United States provides funding for various multicancer screening trials and studies. They also play a crucial role in shaping policies that incentivize or mandate cancer screening.

Moreover, governing bodies of every country also launch public awareness campaigns to promote cancer screening and early detection. These campaigns focus on educating people about the importance of regular screening for cancer and encourage them to get screened. Furthermore, governments can collaborate with private companies and organizations to advance cancer screening technologies. In the case of cancer screening programs, Public-private partnerships (PPPs) may be formed to increase awareness and access to screening, reduce costs, and improve the quality of screening services. Development in the support provided by the government to reduce the prevalence of cancer in every country along with the introduction of new health insurance plans every year is expected to register impressive growth in the global multicancer screening market in upcoming years.

Increase in Geriatric Population

The increasing geriatric population is a significant driver for the growth of the Global Multicancer Screening Market. As of 2023, the number of individuals aged 60 and older worldwide was projected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. This demographic shift is particularly evident in developing regions, where the aging population is growing rapidly. The aging process is associated with a higher risk of developing various types of cancers due to factors such as accumulated genetic mutations and a decline in immune system efficiency. Consequently, there is an increased demand for effective screening technologies to detect cancers at an early, more treatable stage.

Healthcare systems are recognizing the need to implement routine cancer screenings for older individuals, as early detection can significantly improve survival rates. The geriatric population is often more susceptible to multiple comorbidities, and cancer is one of the leading causes of death in this age group. As the incidence of cancer rises with age, healthcare systems and caregivers are seeking comprehensive and non-invasive screening methods that can help detect multiple cancers simultaneously, reducing the burden on the healthcare system while improving patient outcomes.

In addition to medical necessity, there is a heightened awareness among the elderly about the importance of regular health check-ups, including cancer screenings. Many healthcare providers are now offering these services tailored specifically for senior citizens, further boosting market demand. The rise of wearable technologies and at-home testing kits for cancer detection also aligns with the growing geriatric demographic, offering convenience and early intervention opportunities. This convergence of factors underscores the pivotal role of the aging population in driving the expansion of the multicancer screening market.

Download Free Sample Report

Key Market Challenges

Lack of Standardization and Clinical Validation

A significant challenge for the Global Multicancer Screening Market is the lack of standardization and clinical validation of multicancer screening tests. Although several promising technologies have emerged for early cancer detection, many of them still lack universally accepted standards for their application across diverse populations. Variations in testing protocols, detection methods, and diagnostic thresholds can lead to inconsistent results and hinder the reliability of these screening tests. Without a clear, globally recognized standard for conducting multicancer screenings, healthcare providers may be hesitant to adopt these technologies, resulting in slower market growth and adoption.

Clinical validation also remains a barrier. Many of the new diagnostic tests, while innovative, have not been fully validated through large-scale clinical trials. This lack of robust clinical evidence makes it difficult to assess the accuracy, sensitivity, and specificity of these tests, which are critical factors for patient safety and effective treatment. For tests to gain widespread acceptance, especially among regulatory bodies, they must undergo rigorous validation processes that prove their ability to detect cancers early and accurately. The absence of sufficient clinical validation leads to uncertainty regarding the real-world applicability of these tests and may cause hesitancy among healthcare providers and patients. Addressing these challenges is essential to the growth of the market, as the need for clinically proven and standardized tests is critical to ensure the success and widespread use of multicancer screening technologies.

False Positives and Overdiagnosis Risks

One of the key challenges in the Global Multicancer Screening Market is the risk of false positives and overdiagnosis. While early detection of cancer is crucial for improving survival rates, the sensitivity of some screening tests can lead to false positive results. False positives occur when a test incorrectly indicates the presence of cancer in an individual who is actually cancer-free. This not only leads to unnecessary anxiety and emotional distress for patients but also results in additional testing and medical procedures that can be costly, invasive, and potentially harmful.

Overdiagnosis is another concern, especially with advancements in screening technology that may detect cancers that would never have caused harm during a patient’s lifetime. Many cancers detected through screening, particularly in their very early stages, may be slow-growing and not pose an immediate threat to the patient’s health. However, diagnosing and treating these cancers can result in unnecessary treatments, including surgeries, radiation, and chemotherapy, which can have significant side effects and impact the patient’s quality of life.

These risks undermine the effectiveness of multicancer screening initiatives and may deter patients and healthcare providers from fully embracing these technologies. Addressing these challenges requires continuous improvement in the specificity and accuracy of screening tests, alongside a more nuanced understanding of the biology of cancer. It also necessitates better counseling and patient education regarding the potential risks of false positives and overdiagnosis, which can ensure that patients make informed decisions about undergoing screening and treatment options.

Key Market Trends

Integration of Liquid Biopsy and Genomic Technologies

The integration of liquid biopsy and genomic technologies is a key market trend driving the growth of the Global Multicancer Screening Market. Liquid biopsy, a non-invasive diagnostic method, allows for the detection of cancer-related biomarkers from bodily fluids like blood, urine, and saliva. This technology enables the identification of cancer in its early stages, even before symptoms appear, offering a significant advantage over traditional biopsy methods. By detecting circulating tumor DNA (ctDNA), RNA, or exosomes, liquid biopsy allows for real-time monitoring of tumor progression, recurrence, and treatment response, making it an ideal tool for multicancer screening.

Genomic technologies, including next-generation sequencing (NGS) and CRISPR-based gene editing, play a critical role in enhancing the sensitivity and accuracy of liquid biopsy. NGS, for instance, enables the comprehensive analysis of genetic mutations and alterations associated with various cancers, helping to identify multiple cancers simultaneously from a single sample. The combination of liquid biopsy with genomic technologies offers a more precise and comprehensive approach to cancer detection, reducing the risk of false negatives and improving early diagnosis.

As these technologies become more refined and affordable, their integration into multicancer screening programs will revolutionize early cancer detection and prevention. Researchers and healthcare providers are increasingly exploring these tools for broad-spectrum screening across various cancer types, from lung to gastrointestinal cancers. This trend not only improves the speed and efficiency of screening but also reduces the cost of tests, making cancer detection accessible to a wider population.

Growth in Public-Private Partnerships and Research Funding

The growth in public-private partnerships and research funding is a significant trend shaping the Global Multicancer Screening Market. Governments, research institutions, and private organizations are increasingly collaborating to advance the development of multicancer screening technologies. Public-private partnerships (PPPs) are fostering innovation by combining the strengths of both sectors: the public sector's resources and the private sector's technological expertise. This collaboration accelerates research, facilitates large-scale clinical trials, and promotes the development of novel screening tools that can detect multiple cancers simultaneously.

Research funding is also rising as governments and private foundations prioritize cancer detection and early screening. Initiatives like the Cancer Moonshot program in the United States, which aims to reduce cancer death rates and improve cancer screening technologies, are examples of large-scale efforts driving the market. Research funding is not only supporting the development of advanced diagnostic tools but also focusing on regulatory processes and cost-effectiveness to make these tools widely available. These funds are critical for advancing the development of high-accuracy, low-cost, non-invasive screening technologies that can be utilized across diverse populations, including those in resource-limited regions.

This trend is fueling advancements in molecular biology, biomarker discovery, and artificial intelligence (AI) integration into screening methods. Increased investments and collaborative efforts in research are accelerating the availability of reliable and scalable solutions, which in turn makes the screening process more accessible to the general population. The result is a significant shift toward early cancer detection as a standard in medical practice, with potential to reduce mortality rates across various cancer types.

Segmental Insights

Test Type Insights

Based on the Test Type, In-Vitro Diagnostics (IVDs) emerged as the dominant segment in the Global Multicancer Screening Market in 2024. The dominance of IVDs in this market can be attributed to the growing demand for early cancer detection and the increasing adoption of non-invasive testing methods. IVDs enable the detection of genetic biomarkers and mutations associated with various cancers, providing valuable information for early diagnosis and personalized treatment plans. With advancements in technology, IVDs are now able to detect multiple types of cancer from a single blood sample, significantly reducing the need for multiple tests and the associated costs. The high demand for early-stage cancer detection and preventive care is another key factor driving the dominance of IVDs. As IVDs continue to evolve, their accuracy and cost-effectiveness make them the preferred choice for healthcare providers and patients alike. Their growing use in routine cancer screenings further strengthens their position as the leading test type in the multicancer screening market.

Technology Insights

Based on the Technology, Next-Generation Sequencing (NGS) emerged as the dominant segment in the Global Multicancer Screening Market in 2024. The dominance of NGS in the multicancer screening market is driven by its ability to detect multiple cancers simultaneously from a single sample, such as blood or tissue, with high precision. This capability is particularly important in the context of early detection, where identifying cancer at its earliest stages significantly improves treatment outcomes. NGS offers high sensitivity in identifying cancer-related genetic markers, helping clinicians detect a broad range of cancers, including those that may not exhibit symptoms in their early stages. The growing demand for personalized medicine also contributes to the prominence of NGS in cancer screening. By identifying genetic alterations specific to an individual’s cancer, NGS aids in tailoring treatment plans, ensuring more effective and targeted therapies. As the technology continues to advance, NGS is expected to play a crucial role in the future of multicancer screening, enabling earlier and more accurate cancer detection.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the Global Multicancer Screening Market in 2024. This is primarily due to several key factors, including advanced healthcare infrastructure, high adoption rates of cutting-edge diagnostic technologies, and strong investment in research and development. The region boasts a well-established healthcare system with easy access to the latest diagnostic tools, enabling efficient implementation of multicancer screening tests. The increasing focus on early cancer detection, backed by rising awareness about the benefits of early-stage diagnosis, has propelled market growth in North America. The region's significant healthcare expenditure and governmental support for cancer-related initiatives, such as the U.S. Cancer Moonshot program, have further accelerated advancements in cancer detection technologies, including Next-Generation Sequencing (NGS) and In-Vitro Diagnostics (IVDs).

Asia-Pacific emerged as the fastest growing region in the Global Multicancer Screening Market during the forecast period. This is due to the increasing prevalence of cancer, along with growing investments in healthcare infrastructure. Countries like China, India, Japan, and South Korea are seeing significant increases in cancer cases, which is creating a strong demand for more accessible and effective screening methods. The rapid urbanization in these countries, coupled with an aging population, has increased the burden of cancer, thereby driving the need for early detection technologies. Governments in the region are beginning to realize the economic and health benefits of early cancer detection, and they are making efforts to improve healthcare access. These factors have led to the implementation of large-scale multicancer screening programs, with a focus on providing early-stage detection through advanced diagnostic technologies.

Recent Developments

• In May 2025, GRAIL, Inc. announced a partnership with athenahealth to integrate its Galleri multi-cancer early detection (MCED) test into athenaCoordinator Core, part of the athenaOne cloud-based EHR platform. This integration will enable over 160,000 U.S. clinicians using athenahealth’s network to directly order the Galleri test within the EHR system, streamlining lab orders and reducing administrative steps.
• In January 2025, ClearNote Health announced that its Avantect Multi-Cancer Detection Test was selected for the Vanguard Study funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). The test was one of only two chosen after a rigorous evaluation of emerging multi-cancer detection technologies. The Vanguard Study will assess the feasibility of using noninvasive blood-based multi-cancer detection tests in randomized controlled trials (RCTs) to determine their clinical benefit in detecting cancers at early stages.
• In October 2024, SeekIn Inc. showcased its pioneering two-step multi-cancer screening strategy during the Early Detection of Cancer Conference held in San Francisco. The company’s innovative approach is designed to make multi-cancer early detection (MCED) testing more economically viable on a population scale by first implementing a low-cost screening to identify high-risk individuals, followed by more comprehensive testing only where needed.
• In August 2024, Exact Sciences, a leader in cancer diagnostics, announced a significant milestone by enrolling the first patient in its Falcon Registry Real-World Evidence (RWE) study, in partnership with Baylor Scott & White Health, Texas’s largest non-profit healthcare provider. The nationwide, multi-site study is set to enroll up to 25,000 individuals and will assess not only the clinical performance of MCED tests, but also gain valuable insights into patient and provider experiences and the emotional and psychological impacts of early cancer screening.
• In February 2024, the National Institutes of Health (NIH) announced the launch of the Cancer Screening Research Network (CSRN), a major step in advancing the Biden-Harris administration's Cancer Moonshot initiative. Through the National Cancer Institute (NCI), the NIH has committed to funding eight leading research institutions to form the foundation of this network. The CSRN will serve as a national platform to rigorously evaluate emerging early detection technologies, such as blood-based screening and AI-driven diagnostics, with the goal of identifying cancers earlier and improving survival rates.

Key Market Players

• Agilent Technologies, Inc.
• Atara Biotherapeutics, Inc.
• Burning Rock Biotech Limited
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fulgent Genetics, Inc.
• Genecast Biotechnology Co., Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Konica Minolta, Inc.

Report Scope:

In this report, the Global Multicancer Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Multicancer Screening Market, By Test Type:

o   Laboratory Developed Tests (LDTs)

o   In-Vitro Diagnostics (IVDs)

• Multicancer Screening Market, By Technology:

o   Next-Generation Sequencing (NGS)

o   Polymerase Chain Reaction (PCR)

o   Immunohistochemistry (IHC)

o   Fluorescence In-Situ Hybridization (FISH)

o   Others

• Multicancer Screening Market, By Sample:

o   Tissue

o   Blood

o   Saliva and Buccal Swab

o   Others

• Multicancer Screening Market, By Method:

o   DNA

o   RNA

o   Proteins

• Multicancer Screening Market, By Cancer Type:

o   Breast and Gynecologic

o   Gastrointestinal

o   Endocrine

o   Genitourinary

o   Skin

o   Brain/Nervous System

o   Sarcoma

o   Hematological Malignancies

o   Lung

o   Head and Neck

o   Other Cancer Types

• Multicancer Screening Market, By Application:

o   Clinical

o   Research

• Multicancer Screening Market, By End User:

o   Hospitals

o   Diagnostic and Clinical Laboratories

o   Academic Research Institutions

o   Others

• Multicancer Screening Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multicancer Screening Market.

Available Customizations:

Global Multicancer Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Multicancer Screening Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]